Temozolomide and rituximab for relapsed/refractory central nervoussystem lymphoma.

Phase 3

Recruiting

• Conditions: relapsed/refractory central nervous system lymphoma; Lymphoma

• Registration Number: JPRN-jRCTs031180374
• Lead Sponsor: Taoka Kazuki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-18
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Patients with relapsed/refractory central nervous system
lymphoma carrying a measurable lesion on brain MRI.
2. High-dose methotrexate and high-dose cytarabine are
ineffective or intolerable.
3. Absolute neutrophil count >= 1*10^9 /L.
4. Platelet count >= 50*10^9 /L.
5. Tumor cells express CD20.

Exclusion Criteria

1. Presence of uncontrollable infection.
2. Positive for serum anti-HIV antibody.
3. Positive for serum anti-HBV antigen or elevated serum
HBV-DNA level.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall response rate

Secondary Outcome Measures

Name	Time	Method
Progression free survival Overall survival